Olaratumab in the management of advanced soft tissue sarcoma

Abstract

Olaratumab, the first-in-class anti-PDGFRα monoclonal antibody, has been contingently approved in combination with doxorubicin to treat adult patients with advanced soft tissue sarcoma for improving progression-free and overall survival. Olaratumab–doxorubicin combination has tolerable safety profile, which mimics that of doxorubicin monotherapy, with the exception of infusion-related reactions. Survival data of an ongoing confirmatory phase 3 trial are forthcoming to ascertain the optimal role of this product in the management algorithm of advanced soft tissue sarcoma. Active research is ongoing to identify biomarkers predictive of clinical benefit to olaratumab, to expand its utility to the pediatric population, and to explore its safety and efficacy in combination with other active regimens.

Keywords

Soft tissue sarcoma sarcoma anti-PDGFRα monoclonal antibody olaratumab IMC-3G3

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

. Cancer statistics, 2018. Cancer J Clin 2018; 68: 7–30.

National Comprehensive Cancer Network. Soft tissue sarcomas (2018), www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf (accessed 6 July 2018).

Doyle

. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer 2014; 120: 1763–1774.

Fletcher

Hogendoorn

Mertens

et al.

WHO classification of tumours of soft tissue and bone., 4th ed. Lyon, France: IARC Press, 2013.

Ravi

Patel

Benjamin

. Chemotherapy for soft-tissue sarcoma. Oncology 2015; 29: 43–50.

Judson

et al.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15: 415–423.

Ryan

et al.

PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol 2016; 34: 3898–3905.

LARTRUVO – Olaratumab [package insert]. Indianapolis, IN: Eli Lilly and Company, 2017.

Ostman

Heldin

. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001; 80: 1–38.

10.

Heldin

. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 2013; 11: 97–97.

11.

Paulsson

Ehnman

Ostman

. PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol 2014; 10: 1695–708.

12.

Pietras

et al.

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476–5484.

13.

Falcon

et al.

Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol 2011; 178: 2920–2930.

14.

Noujaim

et al.

Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med 2015; 12: 375–384.

15.

Corless

Heinrich

. Molecular classification of GISTs. Nat Rev Cancer 2011; 11: 865–878.

16.

Stacchiotti

et al.

Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012; 30: 914–920.

17.

Kubo

et al.

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119–2129.

18.

et al.

PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012; 72: 4515–4525.

19.

Taniguchi

et al.

PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008; 27: 6550–6560.

20.

Sturzl

et al.

Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 1992; 89: 7046–7050.

21.

Gleevec – Imatinib [package insert]. East Hanover, NJ: Norvartis Pharmaceuticals Corporation, 2017.

22.

van der Graaf

et al.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879–1886.

23.

Zwerner

May

. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 2002; 21: 3847–3854.

24.

Foltz

Karow

Wasserman

. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation 2013; 127: 2222–2230.

25.

Chiorean

et al.

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73: 595–604.

26.

Doi

et al.

Phase I study of olaratumab in Japanese patients with advanced solid tumors. Cancer Sci 2014; 105: 862–869.

27.

Tap

et al.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016; 388: 488–497.

28.

Wagner

Kindler

Gelderblom

et al.

A phase II study of a human anti-PDGFRα monoclonal antibody (Olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol 2017; 28: 541–546.

29.

Lartruvo Vial Selection Guide, www.lartruvo.com/_assets/pdfs/lartruvo-vial-selection-guide-electronic.pdf (accessed 28 May 2018).

30.

Fahrenbruch

et al.

Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the Hematology/Oncology Pharmacy Association. J Oncol Pract 2018; 14: e130–e136.

31.

Olaratumab. Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics, www.micromedexsolutions.com/ (accessed 28 May 2018).

32.

PatientOne. Lilly USA, www.lillypatientone.com/patient/index.html (accessed 28 May 2018).

33.

Zuluaga-Sanchez

et al.

Cost-effectiveness of olaratumab in combination with doxorubicin for patients with soft tissue sarcoma in the United States. Sarcoma 2018; 2018: 6703963–6703963.

34.

National Comprehensive Cancer Network. Myeloid growth factors (Version 2.2016), www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf (accessed 3 July 2018).

35.

Judson

van der Graaf

. Sarcoma: olaratumab – really a breakthrough for soft-tissue sarcomas? Nat Rev Clin Oncol 2016; 13: 534–536.

36.

Schoffski

et al.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387: 1629–1637.

37.

Utsumi T, Hayashi T, Kobayashi N, et al. Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study- [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium, San Antonio, TX, 6–10 December 2016, Philadelphia (PA): AACR; Cancer Res 2017; 77(4 Suppl): Abstract nr P5-15-10.

38.

Eli Lilly and Company. A study of doxorubicin plus olaratumab (LY3012207) in participants with advanced or metastatic soft tissue sarcoma (ANNOUNCE). Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02451943 (accessed 11 July 2018).

39.

Eli Lilly and Company. A study of olaratumab (LY3012207) in participants with advanced soft tissue sarcoma. Bethesda, MD: National Library of Medicine, https://clinicaltrials.gov/ct2/show/NCT02659020 (accessed 11 July 2018).